| Synergy Medical Group, Llc | |
|
777 Avenue C, Bayonne, NJ 07002-2844 | |
| (201) 436-0911 | |
| Not Available |
| Full Name | Synergy Medical Group, Llc |
|---|---|
| Type | Facility |
| Speciality | Pain Medicine - Interventional Pain Medicine |
| Location | 777 Avenue C, Bayonne, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528313137 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | 38MC00645300 (New Jersey) | Secondary |
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | 25MB08234500 (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Synergy Medical Group, Llc 777 Avenue C, Bayonne, NJ 07002-2844 Ph: () - | Synergy Medical Group, Llc 777 Avenue C, Bayonne, NJ 07002-2844 Ph: (201) 436-0911 |
News Archive
For millions of American children and teens playing sports, good nutrition is critical for maximum health, performance and normal growth.
Researchers at the University of Maryland, Baltimore County (UMBC) have developed a method to investigate the quality of healthcare data using a systematic approach, which is based on creating a taxonomy for data defects thorough literature review and examination of data.
Taking a critical step in eliminating confusion around health care costs, as well as addressing a significant need among today's retired workers, Colorado Public Employees' Retirement Association announced it will now offer its retirees in the pre-Medicare program a new hip and knee replacement benefit option called PERACare Select.
Researchers at the 23andMe COVID-19 Team, who help search for genetic links associated with the severity of COVID-19, found that the genes UGT2A1 and UGT2A2 may be associated with the loss of smell in those infected with SARS-CoV-2.
Stemline Therapeutics, Inc. today announced that data from pre-clinical studies of its IL-3R targeting agents, SL-401 and SL-501, in both in vitro and animal models of human chronic myeloid leukemia (CML) have been selected for poster presentation at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009.
› Verified 8 days ago